Adaptimmune Therapeutics (STU:473A) Other Net Income (Loss) : €0.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics Other Net Income (Loss)?

Adaptimmune Therapeutics's Other Net Income (Loss) for the three months ended in Dec. 2024 was €0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.0 Mil.

Adaptimmune Therapeutics's quarterly Other Net Income (Loss) increased from Jun. 2024 (€0.0 Mil) to Sep. 2024 (€0.0 Mil) and increased from Sep. 2024 (€0.0 Mil) to Dec. 2024 (€0.0 Mil).

Adaptimmune Therapeutics's annual Other Net Income (Loss) declined from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€-0.0 Mil) but then increased from Dec. 2023 (€-0.0 Mil) to Dec. 2024 (€0.0 Mil).

Adaptimmune Therapeutics Other Net Income (Loss) Historical Data

The historical data trend for Adaptimmune Therapeutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics Other Net Income (Loss) Chart

Adaptimmune Therapeutics Annual Data

Trend

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

Adaptimmune Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Adaptimmune Therapeutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Adaptimmune Therapeutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptimmune Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (STU:473A) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

ADAP:USA 473A:Germany

Address

60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.adaptimmune.com

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Adaptimmune Therapeutics Headlines

No Headlines